AI-enabled solutions for
drug discovery

We combine human and artificial intelligence to accelerate drug discovery.

Built from decades of proprietary experimental data and decades of expertise in early drug discovery, our expert systems platform informs decision making and enables the selection of candidate drugs for clinical trials and research.

Taking drug discovery to the next level.

Our comprehensive suite of AI models covers all aspects of preclinical drug discovery, from target identification and selection and virtual screening, to pharmacokinetics  and off target pharmacology, including chemical liability assessment and in vitro toxicology. Using proprietary and public databases and software, we evaluate the intellectual property landscape and provide competitive intelligence to de-risk candidate selection for fast transition from in silico to first-time-in-man.

Discover Medicines Hybrid AI Platform

  • System for searching for prospective biotargets.

  • Knowledge base and KGML models for target phenotype relationships

  • A suite of LLM- based tools to access biomedical data, databases, and ML models

  • SMILES based ML models for bioactivity and ADMET property prediction

  • Global Partner Network

    scientific and global resources network tailored specifically to the needs of early programs

  • AI & Machine Learning Enabled

    our platform is AI-enabled and supported by computer aided drug design

  • At the Forefront of Disruptive Science

    global scientific partner network allows us to capitalize on expanding biotech modalities

  • Broad Therapeutic Focus

    high value therapeutic areas, from immunology to oncology, from CNS to infectious diseases

Team of drug discovery innovators.

Our team consists of early drug discovery experts, the brightest academic minds and seasoned life science investors, as well as AI and machine learning innovators with extensive knowledge and decades of proprietary experimental data.

Backed by

Our partners